Upadacitinib in Difficult-to-Treat Patients With RA

Save

Treatment goals can be challenging for those with RA who are bDMARD-IR. Hear Dr. Tesser’s approach and learn about SELECT-BEYOND and SELECT-CHOICE, where upadacitinib was assessed in such patients.

A Patient-Focused Approach to the Treatment of Rheumatoid Arthritis

Save

Do your patients with RA report persistent symptoms despite improved inflammatory markers? Listen to Dr. Wright discuss the importance of patient-focused measures and read about SELECT-COMPARE’s patient-driven data.

The Science of Upadacitinib in Rheumatoid Arthritis

Save

Upadacitinib is a JAK inhibitor that has been studied in a large Phase 3 program in RA, which included 6 trials (5 registrational) and approximately 5000 patients. Here we provide an overview of JAK inhibition as well as a closer look at the long-term efficacy and safety data from the SELECT-COMPARE Phase 3 trial, which evaluated upadacitinib versus adalimumab or placebo in patients with inadequate response to MTX.

Expert-Selected EULAR 2021 Abstracts

Save

Didn’t have time to join EULAR 2021? Listen to a panel of experts as they present their views on the key abstracts in SpA and Still’s disease.

Upadacitinib’s Long Term Efficacy and Safety

Save

Explore upadacitinib’s long-term efficacy through 3 years in the SELECT-COMPARE trial and dig into data for the integrated safety analysis across 6 phase 3 studies with up to ~4.5 years of exposure.

Expert Perspectives on Lupus Nephritis

Save

In this disease education video series from GSK, leading rheumatologists and nephrologists share their perspectives on lupus nephritis and reflect upon the gaps that remain in our understanding and management of the disease.

Axial Involvement in Spondyloarthritis: A Patient-Centered Exploration

Save

Listen to Ethan Craig, MD, MPH discuss 3 of his patient cases to identify and differentiate axial involvement within the spectrum of spondyloarthritis.

The Reflecting Rheum: 2020 SpA and Still’s Disease Highlights

Save

Listen to a discussion of medical experts share their views on the most impactful work done in Spondyloarthritis and Still’s Disease in 2020.

SELECT-COMPARE and SELECT-CHOICE: Evaluating Head-to-Head Trials to Help Inform Treatment Decisions in RA

Save

ACR Convergence 2020 Fireside Chats – Top Abstracts in nr-axSpA, AS, axial PsA and Still’s disease

Save

Head-to-Head Study of Upadacitinib vs Abatacept in Patients with RA and Inadequate Response to Biologics: Results from SELECT-CHOICE

Save

Your patient with rheumatoid arthritis has not responded to their biologic DMARD – now what? This article highlights the results from SELECT-CHOICE, which is the second head-to-head Phase 3 trial of the JAK inhibitor, upadacitinib, in RA. In this study, upadacitinib was evaluated for noninferiority and superiority assessments vs abatacept, in patients with moderate-to-severe RA who had prior inadequate response to biologic DMARD(s).

BASDAI, ASDAS, ASAS, Oh My! Outcome Measures for Axial Spondyloarthritis

Save

Patients with axial spondyloarthritis (axSpA) present with a wide range of symptoms. Given the disease’s heterogeneous presentation, what tools can be used to monitor patients with axSpA and their response to treatment? How can symptoms be tracked and analyzed over time? This article examines some commonly used axSpA disease measures, moving them from esoteric concepts to practical tools for understanding clinical trials and use in everyday practice.